Evidence map›Paper›PMID 34386940›Full record

ReviewProbiotics and antimicrobial proteins2021

Could Probiotics and Postbiotics Function as "Silver Bullet" in the Post-COVID-19 Era?

Svetoslav Dimitrov Todorov, John Robert Tagg, Iskra Vitanova Ivanova

Open access · bronzeAbstract readReview
In one paragraph

Review in Probiotics and antimicrobial proteins, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. From Pre- and Probiotics to Post-Biotics: A Narrative Review.International journal of environmental research and public health · 2021
    Review
  10. Review
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 2 countries.

Svetoslav Dimitrov TodorovProBacLab, Department of Advanced Convergence, Handong Global University, Gyeongbuk, 37554, Pohang, Republic of Korea. slavi310570@abv.bg.ORCID 0000-0002-6377-3305
John Robert TaggBLIS Technologies Ltd, 81 Glasgow Street, South Dunedin, 9012, New Zealand.
Iskra Vitanova IvanovaDepartment of General and Applied Microbiology, Faculty of Biology, Sofia University St. Kliment Ohridski, 8 Dragan Tzankov Blvd, 1164, Sofia, Bulgaria.
Handong Global University · KRSofia University "St. Kliment Ohridski" · BG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We are currently experiencing the realities of the most severe pandemic within living memory, with major impacts on the health and economic well-being of our planet. The scientific community has demonstrated an unprecedented mobilization capability, with the rapid development of vaccines and drugs targeting the protection of human life and palliative measures for infected individuals. However, are we adequately prepared for ongoing defense against COVID-19 and its variants in the post-pandemic world? Moreover, are we equipped to provide a satisfactory quality of life for individuals who are recovering from COVID-19 disease? What are the possibilities for the acceleration of the recovery process? Here, we give special consideration to the potential and already-demonstrated role of probiotics and traditional medical approaches to the management of current and potential future encounters with our major virus adversaries.

Indexed as

COVID-19 Drug TreatmentAnimalsCOVID-19HumansProbioticsQuality of LifeAntimicrobial peptidesBacteriocinsCoronavirus disease-19 (COVID-19)Lactic acid bacteriaProbioticsTraditional medicine

Identifiers

PMID34386940
PMCPMC8360758
OpenAlexW3193151860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.